Information Provided By: 
Fly News Breaks for October 28, 2015
NUVA
Oct 28, 2015 | 05:57 EDT
Piper Jaffray analyst Matt O'Brien says investors should not pick on NuVasive's Q3 results as the company delivered in-line sales and better than expected earnings in the face of international and biologics headwinds. He continues to recommend purchase of the stock with an Overweight rating and $59 price target.
News For NUVA From the Last 2 Days
There are no results for your query NUVA
